FY2025 · ended Dec 31, 2025 · Revenue $6.16M, -34.2% YoY · Filed Mar 16, 2026
bioAffinity Technologies, Inc. (BIAF) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $6.2 million and a net loss of $14.9 million. Free cash flow was -$9.4 million. As of Jun 30, 2026 it held $2.4 million in cash and investments and $1.6 million in total debt.
Revenue (TTM)
$5.90M
-23.2% vs year-ago TTM
Net income (TTM)
$-15.19M
-29.9% vs year-ago TTM
Operating cash flow (TTM)
$-11.47M
-49.4% vs year-ago TTM
Free cash flow (TTM)
$-11.56M
-49.2% vs year-ago TTM
EPS (TTM)
$-4.00
-256.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.50M
-75.4% vs prior year
Net cash
$793,740
as of Jun 30, 2026
Operating margin
-209.8%
FY 2026
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- BIAF (Nasdaq), BIAFW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1712762
- Former names
- bioAffinity Technologies, Inc. (until Nov 3, 2026)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $2.5M | $4,803 |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M |
| Diluted EPS | -$8.66 | -$22.50 | -$0.91 | — |
| Operating cash flow | -$9.3M | -$7.3M | -$6.0M | -$4.1M |
| Free cash flow | -$9.4M | -$7.3M | -$6.1M | -$4.3M |
| Total assets | $11.0M | $6.5M | $8.2M | $12.2M |
| Total liabilities | $3.7M | $3.9M | $3.4M | $1.1M |
| Stockholders' equity | $7.3M | $2.6M | $4.9M | $11.0M |
| Cash and investments | $6.4M | $1.1M | $2.8M | $11.4M |
| Total debt | $1.0M | $1.3M | $1.6M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 6, 2026 |
All 399 bioAffinity Technologies, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.